Back to Newsroom
Back to Newsroom

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FLDM, BMRN and LOOP

Tuesday, 27 October 2020 11:40 AM

The Gross Law Firm

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / October 27, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly-traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Fluidigm Corporation (NASDAQ:FLDM)

Investors Affected: February 7, 2019 - November 5, 2019

A class action has commenced on behalf of certain shareholders in Fluidigm Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Fluidigm was experiencing longer sales cycles; (2) as a result, Fluidigm's revenue was reasonably likely to decline; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/fluidigm-corporation-loss-submission-form/?id=10491&from=1.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Investors Affected: February 28, 2020 - August 18, 2020

A class action has commenced on behalf of certain shareholders in BioMarin Pharmaceutical Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/biomarin-pharmaceutical-inc-loss-submission-form/?id=10491&from=1.

Loop Industries, Inc. (NASDAQ:LOOP)

Investors Affected: September 24, 2018 - October 12, 2020

A class action has commenced on behalf of certain shareholders in Loop Industries, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Loop scientists were encouraged to misrepresent the results of Loop's purportedly proprietary process; (2) Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) as a result, the Company was unlikely to realize the purported benefits of Loop's announced partnerships with Indorama Ventures Public Company Limited and thyssenkrupp Industrial Solutions; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/loop-industries-inc-loss-submission-form/?id=10491&from=1.

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: